These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8749371)

  • 21. Pyridoxal-5'-phosphate-dependent catalytic antibodies.
    Gramatikova S; Mouratou B; Stetefeld J; Mehta PK; Christen P
    J Immunol Methods; 2002 Nov; 269(1-2):99-110. PubMed ID: 12379355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routes to catalysis: structure of a catalytic antibody and comparison with its natural counterpart.
    Haynes MR; Stura EA; Hilvert D; Wilson IA
    Science; 1994 Feb; 263(5147):646-52. PubMed ID: 8303271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward the antibody-catalyzed chemiluminescence. Design and synthesis of hapten.
    Sawa M; Imaeda Y; Hiratake J; Fujii R; Umeshita R; Watanabe M; Kondo H; Oda J
    Bioorg Med Chem Lett; 1998 Mar; 8(6):647-52. PubMed ID: 9871576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catalysis of decarboxylation by a preorganized heterogeneous microenvironment: crystal structures of abzyme 21D8.
    Hotta K; Lange H; Tantillo DJ; Houk KN; Hilvert D; Wilson IA
    J Mol Biol; 2000 Oct; 302(5):1213-25. PubMed ID: 11183784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similarities of hydrolytic antibodies revealed by their X-ray structures: a review.
    Charbonnier JB; Gigant B; Golinelli-Pimpaneau B; Knossow M
    Biochimie; 1997 Nov; 79(11):653-60. PubMed ID: 9479447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of shape complementarity and catalytic efficiency from a primordial antibody template.
    Xu J; Deng Q; Chen J; Houk KN; Bartek J; Hilvert D; Wilson IA
    Science; 1999 Dec; 286(5448):2345-8. PubMed ID: 10600746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolutionary chemistry: getting there from here.
    Joyce GF
    Science; 1997 Jun; 276(5319):1658-9. PubMed ID: 9206829
    [No Abstract]   [Full Text] [Related]  

  • 28. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
    Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
    Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes.
    Wagner J; Lerner RA; Barbas CF
    Science; 1995 Dec; 270(5243):1797-800. PubMed ID: 8525368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Site-Directed Chemical Mutations on Abzymes: Large Rate Accelerations in the Catalysis by Exchanging the Functionalized Small Nonprotein Components.
    Ishikawa F; Shirahashi M; Hayakawa H; Yamaguchi A; Hirokawa T; Tsumuraya T; Fujii I
    ACS Chem Biol; 2016 Oct; 11(10):2803-2811. PubMed ID: 27552288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding and catalysis: a thermodynamic study on a catalytic antibody system.
    Wade H; Scanlan TS
    Chembiochem; 2003 Jun; 4(6):537-40. PubMed ID: 12794866
    [No Abstract]   [Full Text] [Related]  

  • 33. Design and synthesis of an alpha,alpha-difluorophosphinate hapten for antibody-catalyzed hydrolysis of organophosphorus nerve agents.
    Vayron P; Renard PY; Valleix A; Mioskowski C
    Chemistry; 2000 Mar; 6(6):1050-63. PubMed ID: 10785826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The structural and functional basis of antibody catalysis.
    Wade H; Scanlan TS
    Annu Rev Biophys Biomol Struct; 1997; 26():461-93. PubMed ID: 9241427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
    Odenbaugh AL; Helms ED; Iverson BL
    Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural evidence for a programmed general base in the active site of a catalytic antibody.
    Golinelli-Pimpaneau B; Goncalves O; Dintinger T; Blanchard D; Knossow M; Tellier C
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9892-5. PubMed ID: 10963661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyclonal antibody catalytic variability.
    Stephens DB; Thomas RE; Stanton JF; Iverson BL
    Biochem J; 1998 May; 332 ( Pt 1)(Pt 1):127-34. PubMed ID: 9576860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural convergence in the active sites of a family of catalytic antibodies.
    Charbonnier JB; Golinelli-Pimpaneau B; Gigant B; Tawfik DS; Chap R; Schindler DG; Kim SH; Green BS; Eshhar Z; Knossow M
    Science; 1997 Feb; 275(5303):1140-2. PubMed ID: 9027317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A catalytic antibody against a tocopherol cyclase inhibitor.
    Manetsch R; Zheng L; Reymond MT; Woggon WD; Reymond JL
    Chemistry; 2004 May; 10(10):2487-506. PubMed ID: 15146522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Origins and predictions of stereoselective antibody catalysis: theoretical analysis of Diels-Alder catalysis by 39A11 and its germ-line antibody.
    Zhang X; Deng Q; Yoo SH; Houk KN
    J Org Chem; 2002 Dec; 67(25):9043-53. PubMed ID: 12467427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.